In this podcast, liver cancer experts Prof. Amit Singal and Assoc. Prof Neil Mehta discuss recent advances in systemic and locoregional therapy for advanced and early stage hepatocellular carcinoma (HCC). They focus on the role of immunotherapy and review data from three major congresses in 2022 (ASCO, WCGIC and ILC) together with recent publications.
Prof. Amit Singal is Director of Liver Cancer Program at UT Southwestern Medical Center, Dallas, TX, USA and Assoc. Prof. Neil Mehta is Director of Liver Cancer Program at University of California San Francisco, USA.
Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available...
What are the common pre-analytical phase challenges in lung cancer, and how can we overcome them? Why is it important to identify genetic alterations?...
Episode 1: Identifying HER2-directed NSCLC: The Medical Oncologist and Pathologist perspectives This is the first episode of a two-part series on the HER2 diagnostic...